Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

The influence of statin medications on prostate-specific antigen levels.

Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ.

J Natl Cancer Inst. 2008 Nov 5;100(21):1511-8. doi: 10.1093/jnci/djn362.

3.
4.

[Pleiotropic effects of statins].

Mennickent C S, Bravo D M, Calvo M C, Avello L M.

Rev Med Chil. 2008 Jun;136(6):775-82. doi: /S0034-98872008000600014. Review. Spanish.

5.

[Selection of statin considering the HDL cholesterol level].

Kalina A.

Orv Hetil. 2006 Nov 26;147(47):2279-81. Review. Hungarian.

PMID:
17380690
6.

Newer HMG-CoA reductase inhibitor (statin) therapies.

Brinton EA.

Clin Cardiol. 2001;24(7 Suppl):II-10-3. Review.

7.

Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis.

Genser B, Grammer TB, Stojakovic T, Siekmeier R, März W.

Int J Clin Pharmacol Ther. 2008 Oct;46(10):497-510. Review.

PMID:
18826864
8.

Treating dyslipidemia with statins: the risk-benefit profile.

Clark LT.

Am Heart J. 2003 Mar;145(3):387-96. Review.

PMID:
12660659
9.

[Prostate cancer].

Uchida K, Akaza H.

Gan To Kagaku Ryoho. 2001 Oct;28(10):1469-74. Review. Japanese.

PMID:
11681260
10.
11.

[The role of HDL in the prevention of cardiovascular events].

Paragh G, Harangi M.

Orv Hetil. 2001 Jan 21;142(3):121-6. Review. Hungarian.

PMID:
11217160
12.
13.

[Statins: similarities and differences in the pharmacological, clinical and laboratory aspects].

Motti C, Gnasso A, Cortese C.

Ann Ital Med Int. 2000 Jan-Mar;15(1):96-102. Review. Italian.

PMID:
10842898
14.

Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.

Plakogiannis R, Cohen H.

Ann Pharmacother. 2007 Jan;41(1):106-10. Review.

PMID:
17200427
15.

Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?

Ray KK, Cannon CP, Ganz P.

Am J Cardiol. 2006 Dec 4;98(11A):18P-25P. Review.

PMID:
17126675
16.

Statins and C-reactive protein levels.

Asher J, Houston M.

J Clin Hypertens (Greenwich). 2007 Aug;9(8):622-8. Review.

17.

Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.

Schröder FH, Roobol MJ.

Curr Opin Urol. 2009 May;19(3):227-31. doi: 10.1097/MOU.0b013e328329a2d0. Review.

PMID:
19357513
18.

[Biological markers of prostate cancer].

Seitz C, Djavan B.

Ann Urol (Paris). 2006 Dec;40(6):329-35. Review. French.

PMID:
17214230
19.

Prostate-specific antigen in clinical practice.

Loeb S, Catalona WJ.

Cancer Lett. 2007 Apr 28;249(1):30-9. Review.

PMID:
17258389
20.

The comparability of models for predicting the risk of a positive prostate biopsy with prostate-specific antigen alone: a systematic review.

Schröder F, Kattan MW.

Eur Urol. 2008 Aug;54(2):274-90. doi: 10.1016/j.eururo.2008.05.022. Review.

PMID:
18511177
Items per page

Supplemental Content

Support Center